Abstract 106P
Background
Stage I-III squamous cell cancers (SCC) of the anal canal are treated with definitive concurrent chemoradiotherapy. Capecitabine (Cape) and mitomycin-C (MMC) chemotherapy is an approved concurrent regimen, but with limited evidence.
Methods
A retrospective analysis of stage I-III SCC patients treated at Tata Memorial hospital with concurrent Cape-MMC (Capecitabine 1250mg/m2 PO continuous with IV Mitomycin C 12mg/m2 on D1) based chemoradiotherapy from March 2014 to March 2020 was conducted. Patients were staged as per American Joint Committee on Cancer, seventh edition. The primary outcome of the study was recurrence-free survival (RFS). Overall survival (OS) and RFS were calculated by Kaplan-Meier estimates.
Results
Two hundred and twenty-six patients were included in the study, with the median age being 58 (range: 22-81) years. Stage I, stage II, and stage III cancers were seen in 1(0.4%), 62 (27.4%), and 163 (72.1%) patients, respectively. Patients received a median 45 Gy (range; 20-63) in 25 fractions as definitive radiotherapy with concurrent Cape-MMC. Response evaluation at 6 months was available in 190 patients, with 51 patients (27%) having local residual or progressive disease. Nine patients (4%) underwent salvage surgery. At a median follow up of 28 months, 38 recurrences had occurred, with 13 patients having only local recurrence while 25 patients had distant metastasis, with or without local recurrences. The median 2-year RFS was 82%, while median 2 years OS was 85%. Patients with stage III disease had inferior RFS as compared to patients with stage I/II disease (2 year RFS: 78% vs. 90%; p=0.042) Common grade 3 and grade 4 toxicities were local skin reactions in 44 (21.4%), neutropenia and thrombocytopenia in 9 (4.4%) patients, respectively.
Conclusions
The current study using chemoradiation with Cape-MMC is a large study in predominantly stage III anal canal cancers and shows excellent loco-regional control rates and tolerance in comparison to the traditional 5 fluorouracil-based regimens.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session